ACE2 and COVID-19: As ACE2 contributes to lung inflammation, Apeiron Biologics (Europe) has received approval to test a human recombinant soluble ACE2 (hrsACE2 [APN01; Apeiron Biologics, Vienna, Austria]) in COVID-19 patients [122].